{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T18:32:12Z","timestamp":1794335532745,"version":"4.9.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,2,5]],"date-time":"2021-02-05T00:00:00Z","timestamp":1612483200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,2,5]],"date-time":"2021-02-05T00:00:00Z","timestamp":1612483200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81871645"],"award-info":[{"award-number":["81871645"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["61603092"],"award-info":[{"award-number":["61603092"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81500451"],"award-info":[{"award-number":["81500451"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81100285"],"award-info":[{"award-number":["81100285"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Basic Research Program of China","doi-asserted-by":"publisher","award":["grant number 2015CB553800"],"award-info":[{"award-number":["grant number 2015CB553800"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Tenofovir and entecavir are currently designated as the preferred oral antiviral drugs for chronic hepatitis B. However, only less than 40% of patients can achieve HBeAg seroconversion. We aim at investigating the role of intestinal microbiome in HBeAg seroconversion induced by oral antiviral therapy and describe multi-omics characteristics of HBeAg seroconversion associated intestinal flora. In this study, we prospectively collected fecal samples at baseline from the patients with HBeAg positive chronic hepatitis B who would have oral antiviral therapy. 16S rDNA sequencing and metabolomics were performed. We identified HBeAg seroconversion-related microbial signature and constructed prediction model for HBeAg seroconversion. Thirty-seven of these subjects achieved HBeAg seroconversion within 156\u00a0weeks after the initiation of oral antiviral therapy, while 41 subjects remained HBeAg positive even after over 156\u00a0weeks of therapy. A computational statistical and machine learning approach allowed us to identify a microbial signature for HBeAg seroconversion. Using random forest method, we further constructed a classifier based on the microbial signature, with area under curve being 0.749 for the test set. Patients who achieved HBeAg seroconversion tended to have lower abundance of certain fecal metabolites such as essential amino acids, and several dipeptides. By analyzing the fecal microbiota from the patients with and without HBeAg seroconversion, we showed intestinal microbiome play a critical role in HBeAg seroconversion induced by oral antiviral therapy. We also identified intestinal microbial signature that is associated with HBeAg seroconversion after oral antiviral therapy.<\/jats:p>","DOI":"10.1038\/s41598-021-82939-1","type":"journal-article","created":{"date-parts":[[2021,2,5]],"date-time":"2021-02-05T11:38:05Z","timestamp":1612525085000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Meta-omics characteristics of intestinal microbiota associated to HBeAg seroconversion induced by oral antiviral therapy"],"prefix":"10.1038","volume":"11","author":[{"given":"Yu-Li","family":"Zeng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Jun","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Fang","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Lu","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Bin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Ming","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pan","family":"You","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei-Zhu","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaming","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuan","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben-Chang","family":"Shia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian-Jun","family":"Niu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin-Shui","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,2,5]]},"reference":[{"key":"82939_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12072-015-9675-4","volume":"10","author":"SK Sarin","year":"2016","unstructured":"Sarin, S. K. et al. Asian-Pacific clinical practice guidelines on the management of hepatitis B: A 2015 update. Hepatol. Int. 10, 1\u201398. https:\/\/doi.org\/10.1007\/s12072-015-9675-4 (2016).","journal-title":"Hepatol. Int."},{"key":"82939_CR2","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","volume":"67","author":"European Association for the Study of the Liver","year":"2017","unstructured":"European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J. Hepatol. 67, 370\u2013398. https:\/\/doi.org\/10.1016\/j.jhep.2017.03.021 (2017).","journal-title":"J. Hepatol."},{"key":"82939_CR3","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1002\/hep.22760","volume":"49","author":"MR Brunetto","year":"2009","unstructured":"Brunetto, M. R. et al. Hepatitis B virus surface antigen levels: A guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B. Hepatology 49, 1141\u20131150. https:\/\/doi.org\/10.1002\/hep.22760 (2009).","journal-title":"Hepatology"},{"key":"82939_CR4","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1056\/NEJMoa040431","volume":"351","author":"P Marcellin","year":"2004","unstructured":"Marcellin, P. et al. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N. Engl. J. Med. 351, 1206\u20131217. https:\/\/doi.org\/10.1056\/NEJMoa040431 (2004).","journal-title":"N. Engl. J. Med."},{"key":"82939_CR5","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1056\/NEJMoa051285","volume":"354","author":"TT Chang","year":"2006","unstructured":"Chang, T. T. et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N. Engl. J. Med. 354, 1001\u20131010. https:\/\/doi.org\/10.1056\/NEJMoa051285 (2006).","journal-title":"N. Engl. J. Med."},{"key":"82939_CR6","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1002\/hep.23327","volume":"51","author":"TT Chang","year":"2010","unstructured":"Chang, T. T. et al. Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B. Hepatology 51, 422\u2013430. https:\/\/doi.org\/10.1002\/hep.23327 (2010).","journal-title":"Hepatology"},{"key":"82939_CR7","doi-asserted-by":"publisher","first-page":"2442","DOI":"10.1056\/NEJMoa0802878","volume":"359","author":"P Marcellin","year":"2008","unstructured":"Marcellin, P. et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N. Engl. J. Med. 359, 2442\u20132455. https:\/\/doi.org\/10.1056\/NEJMoa0802878 (2008).","journal-title":"N. Engl. J. Med."},{"key":"82939_CR8","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1111\/jvh.12149","volume":"21","author":"AK Singh","year":"2014","unstructured":"Singh, A. K., Sharma, M. K., Hissar, S. S., Gupta, E. & Sarin, S. K. Relevance of hepatitis B surface antigen levels in patients with chronic hepatitis B during 5 year of tenofovir treatment. J. Viral. Hepat. 21, 439\u2013446. https:\/\/doi.org\/10.1111\/jvh.12149 (2014).","journal-title":"J. Viral. Hepat."},{"key":"82939_CR9","doi-asserted-by":"publisher","first-page":"2175","DOI":"10.1073\/pnas.1424775112","volume":"112","author":"HH Chou","year":"2015","unstructured":"Chou, H. H. et al. Age-related immune clearance of hepatitis B virus infection requires the establishment of gut microbiota. Proc. Natl. Acad. Sci. U. S. A. 112, 2175\u20132180. https:\/\/doi.org\/10.1073\/pnas.1424775112 (2015).","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"82939_CR10","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1002\/hep.29008","volume":"65","author":"YD Ren","year":"2017","unstructured":"Ren, Y. D. et al. Fecal microbiota transplantation induces hepatitis B virus e-antigen (HBeAg) clearance in patients with positive HBeAg after long-term antiviral therapy. Hepatology 65, 1765\u20131768. https:\/\/doi.org\/10.1002\/hep.29008 (2017).","journal-title":"Hepatology"},{"key":"82939_CR11","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1038\/nature11552","volume":"489","author":"V Tremaroli","year":"2012","unstructured":"Tremaroli, V. & Backhed, F. Functional interactions between the gut microbiota and host metabolism. Nature 489, 242\u2013249. https:\/\/doi.org\/10.1038\/nature11552 (2012).","journal-title":"Nature"},{"key":"82939_CR12","doi-asserted-by":"publisher","first-page":"D457","DOI":"10.1093\/nar\/gkv1070","volume":"44","author":"M Kanehisa","year":"2016","unstructured":"Kanehisa, M., Sato, Y., Kawashima, M., Furumichi, M. & Tanabe, M. KEGG as a reference resource for gene and protein annotation. Nucleic Acids Res. 44, D457-462. https:\/\/doi.org\/10.1093\/nar\/gkv1070 (2016).","journal-title":"Nucleic Acids Res."},{"key":"82939_CR13","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1093\/nar\/28.1.27","volume":"28","author":"M Kanehisa","year":"2000","unstructured":"Kanehisa, M. & Goto, S. KEGG: Kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 28, 27\u201330. https:\/\/doi.org\/10.1093\/nar\/28.1.27 (2000).","journal-title":"Nucleic Acids Res."},{"key":"82939_CR14","doi-asserted-by":"publisher","first-page":"2498","DOI":"10.1101\/gr.1239303","volume":"13","author":"P Shannon","year":"2003","unstructured":"Shannon, P. et al. Cytoscape: A software environment for integrated models of biomolecular interaction networks. Genome Res. 13, 2498\u20132504. https:\/\/doi.org\/10.1101\/gr.1239303 (2003).","journal-title":"Genome Res."},{"key":"82939_CR15","doi-asserted-by":"publisher","first-page":"e61217","DOI":"10.1371\/journal.pone.0061217","volume":"8","author":"PJ McMurdie","year":"2013","unstructured":"McMurdie, P. J. & Holmes, S. phyloseq: An R package for reproducible interactive analysis and graphics of microbiome census data. PLoS ONE 8, e61217. https:\/\/doi.org\/10.1371\/journal.pone.0061217 (2013).","journal-title":"PLoS ONE"},{"key":"82939_CR16","doi-asserted-by":"publisher","first-page":"e30126","DOI":"10.1371\/journal.pone.0030126","volume":"7","author":"I Holmes","year":"2012","unstructured":"Holmes, I., Harris, K. & Quince, C. Dirichlet multinomial mixtures: Generative models for microbial metagenomics. PLoS ONE 7, e30126. https:\/\/doi.org\/10.1371\/journal.pone.0030126 (2012).","journal-title":"PLoS ONE"},{"key":"82939_CR17","doi-asserted-by":"publisher","first-page":"2002","DOI":"10.1053\/j.gastro.2009.08.061","volume":"137","author":"EH Buster","year":"2009","unstructured":"Buster, E. H. et al. Factors that predict response of patients with hepatitis B e antigen-positive chronic hepatitis B to peginterferon-alfa. Gastroenterology 137, 2002\u20132009. https:\/\/doi.org\/10.1053\/j.gastro.2009.08.061 (2009).","journal-title":"Gastroenterology"},{"key":"82939_CR18","doi-asserted-by":"publisher","first-page":"3465","DOI":"10.3748\/wjg.v16.i27.3465","volume":"16","author":"QG Mao","year":"2010","unstructured":"Mao, Q. G. et al. Precise prediction model and simplified scoring system for sustained combined response to interferon-alpha. World J. Gastroenterol. 16, 3465\u20133471. https:\/\/doi.org\/10.3748\/wjg.v16.i27.3465 (2010).","journal-title":"World J. Gastroenterol."},{"key":"82939_CR19","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1002\/hep.26436","volume":"58","author":"MJ Sonneveld","year":"2013","unstructured":"Sonneveld, M. J. et al. Response-guided peginterferon therapy in hepatitis B e antigen-positive chronic hepatitis B using serum hepatitis B surface antigen levels. Hepatology 58, 872\u2013880. https:\/\/doi.org\/10.1002\/hep.26436 (2013).","journal-title":"Hepatology"},{"key":"82939_CR20","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1111\/jgh.12932","volume":"30","author":"Y Chen","year":"2015","unstructured":"Chen, Y. et al. Gut dysbiosis in acute-on-chronic liver failure and its predictive value for mortality. J. Gastroenterol. Hepatol. 30, 1429\u20131437. https:\/\/doi.org\/10.1111\/jgh.12932 (2015).","journal-title":"J. Gastroenterol. Hepatol."},{"key":"82939_CR21","doi-asserted-by":"publisher","first-page":"2222","DOI":"10.3389\/fmicb.2017.02222","volume":"8","author":"J Wang","year":"2017","unstructured":"Wang, J. et al. Gut microbial dysbiosis is associated with altered hepatic functions and serum metabolites in chronic hepatitis B patients. Front. Microbiol. 8, 2222. https:\/\/doi.org\/10.3389\/fmicb.2017.02222 (2017).","journal-title":"Front. Microbiol."},{"key":"82939_CR22","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1002\/hep.28356","volume":"63","author":"J Boursier","year":"2016","unstructured":"Boursier, J. et al. The severity of nonalcoholic fatty liver disease is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota. Hepatology 63, 764\u2013775. https:\/\/doi.org\/10.1002\/hep.28356 (2016).","journal-title":"Hepatology"},{"key":"82939_CR23","doi-asserted-by":"publisher","DOI":"10.1002\/hep.30036","author":"FR Ponziani","year":"2018","unstructured":"Ponziani, F. R. et al. Hepatocellular carcinoma is associated with gut microbiota profile and inflammation in nonalcoholic fatty liver disease. Hepatology https:\/\/doi.org\/10.1002\/hep.30036 (2018).","journal-title":"Hepatology"},{"key":"82939_CR24","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1002\/hep.24423","volume":"54","author":"Y Chen","year":"2011","unstructured":"Chen, Y. et al. Characterization of fecal microbial communities in patients with liver cirrhosis. Hepatology 54, 562\u2013572. https:\/\/doi.org\/10.1002\/hep.24423 (2011).","journal-title":"Hepatology"},{"key":"82939_CR25","doi-asserted-by":"publisher","DOI":"10.1128\/mBio.02289-17","author":"AN Jacobson","year":"2018","unstructured":"Jacobson, A. N., Choudhury, B. P. & Fischbach, M. A. The biosynthesis of lipooligosaccharide from Bacteroides thetaiotaomicron. MBio https:\/\/doi.org\/10.1128\/mBio.02289-17 (2018).","journal-title":"MBio"},{"key":"82939_CR26","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.tim.2017.07.006","volume":"26","author":"KN Tsai","year":"2018","unstructured":"Tsai, K. N., Kuo, C. F. & Ou, J. J. Mechanisms of hepatitis B virus persistence. Trends Microbiol. 26, 33\u201342. https:\/\/doi.org\/10.1016\/j.tim.2017.07.006 (2018).","journal-title":"Trends Microbiol."},{"key":"82939_CR27","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1186\/1471-2180-9-123","volume":"9","author":"D Mariat","year":"2009","unstructured":"Mariat, D. et al. The Firmicutes\/Bacteroidetes ratio of the human microbiota changes with age. BMC Microbiol. 9, 123. https:\/\/doi.org\/10.1186\/1471-2180-9-123 (2009).","journal-title":"BMC Microbiol."},{"key":"82939_CR28","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.jhep.2008.12.019","volume":"51","author":"S Zeuzem","year":"2009","unstructured":"Zeuzem, S. et al. Baseline characteristics and early on-treatment response predict the outcomes of 2 years of telbivudine treatment of chronic hepatitis B. J. Hepatol. 51, 11\u201320. https:\/\/doi.org\/10.1016\/j.jhep.2008.12.019 (2009).","journal-title":"J. Hepatol."},{"key":"82939_CR29","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1002\/hep.23323","volume":"51","author":"HW Lee","year":"2010","unstructured":"Lee, H. W. et al. Lamivudine maintenance beyond one year after HBeAg seroconversion is a major factor for sustained virologic response in HBeAg-positive chronic hepatitis B. Hepatology 51, 415\u2013421. https:\/\/doi.org\/10.1002\/hep.23323 (2010).","journal-title":"Hepatology"},{"key":"82939_CR30","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1159\/000086061","volume":"48","author":"SK Yoon","year":"2005","unstructured":"Yoon, S. K. et al. Long-term results of lamivudine monotherapy in Korean patients with HBeAg-positive chronic hepatitis B: Response and relapse rates, and factors related to durability of HBeAg seroconversion. Intervirology 48, 341\u2013349. https:\/\/doi.org\/10.1159\/000086061 (2005).","journal-title":"Intervirology"},{"key":"82939_CR31","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/j.micpath.2018.10.005","volume":"125","author":"Y Yang","year":"2018","unstructured":"Yang, Y., Gu, H., Sun, Q. & Wang, J. Effects of Christensenella minuta lipopolysaccharide on RAW 2647 macrophages activation. Microb. Pathog. 125, 411\u2013417. https:\/\/doi.org\/10.1016\/j.micpath.2018.10.005 (2018).","journal-title":"Microb. Pathog."},{"key":"82939_CR32","doi-asserted-by":"publisher","first-page":"2045","DOI":"10.1007\/s10096-011-1538-x","volume":"31","author":"J Yang","year":"2012","unstructured":"Yang, J. et al. Correlation between plasma amino acid profiles and the various stages of hepatitis B infection. Eur. J. Clin. Microbiol. Infect. Dis. 31, 2045\u20132052. https:\/\/doi.org\/10.1007\/s10096-011-1538-x (2012).","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"82939_CR33","doi-asserted-by":"publisher","first-page":"319","DOI":"10.3389\/fimmu.2018.00319","volume":"9","author":"W Ren","year":"2018","unstructured":"Ren, W. et al. Amino acids as mediators of metabolic cross talk between host and pathogen. Front. Immunol. 9, 319. https:\/\/doi.org\/10.3389\/fimmu.2018.00319 (2018).","journal-title":"Front. Immunol."},{"key":"82939_CR34","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1038\/ni.3542","volume":"17","author":"EY Lee","year":"2016","unstructured":"Lee, E. Y. et al. Infection-specific phosphorylation of glutamyl-prolyl tRNA synthetase induces antiviral immunity. Nat. Immunol. 17, 1252\u20131262. https:\/\/doi.org\/10.1038\/ni.3542 (2016).","journal-title":"Nat. Immunol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-82939-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-82939-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-82939-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T03:24:32Z","timestamp":1670037872000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-82939-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,5]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["82939"],"URL":"https:\/\/doi.org\/10.1038\/s41598-021-82939-1","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,5]]},"assertion":[{"value":"21 July 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 January 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 February 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"3253"}}